

July 30, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (BC-09)

PARITAPREVIR

PRONUNCIATION

par" i ta' pre vir


THERAPEUTIC CLAIM

Treatment of hepatitis C

CHEMICAL NAMES

1. Cyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14a(5*H*)-carboxamide, *N*-(cyclopropylsulfonyl)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydro-6-[[5-methyl-2-pyrazinyl)carbonyl]amino]-5,16-dioxo-2-(6-phenanthridinyloxy)-, (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-
2. (2*R*,6*S*,12*Z*,13a*S*,14a*R*,16a*S*)-*N*-(cyclopropylsulfonyl)-6-[[5-methylpyrazin-2-yl)carbonyl]amino]-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-*a*][1,4]diazacyclopentadecine-14a(5*H*)-carboxamide

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₄₀H₄₃N₇O₇S

MOLECULAR WEIGHT

765.9

TRADEMARK

None as yet

SPONSOR

AbbVie, Inc.

CODE DESIGNATIONS

ABT-450

CAS REGISTRY NUMBER 1216941-48-8

UNII OU2YM37K86

WHO NUMBER 9739

SCS